Charles River Labs, Chicago, IL, USA.
Tango Therapeutics Inc. 901 Brookline Avenue, Suite 901, Boston, MA, 02215, USA; Jnana Therapeutics. One Design Center Place, Suite 19-400, Boston, MA, 02210, USA.
SLAS Technol. 2024 Oct;29(5):100173. doi: 10.1016/j.slast.2024.100173. Epub 2024 Jul 31.
Polymerase β (POLB), with dual functionality as a lyase and polymerase, plays a critical role in the base excision repair (BER) pathway to maintain genomic stability. POLB knockout and rescue studies in BRCA1/2-mutant cancer cell lines revealed that inhibition of lyase and polymerase activity is required for the synthetic lethal interaction observed with PARP inhibitors, highlighting POLB as a valuable therapeutic target. Traditional biochemical assays to screen for enzyme inhibitors focus on a single substrate to product relationship and limit the comprehensive analysis of enzymes such as POLB that utilize multiple substrates or catalyze a multi-step reaction. This report describes the first high-throughput mass spectrometry-based screen to measure the two distinct biochemical activities of POLB in a single assay using a duplexed self-assembled monolayer desorption ionization (SAMDI) mass spectrometry methodology. A multiplexed assay for POLB dual enzymatic activities was developed optimizing for kinetically balanced conditions and a collection of 200,000 diverse small molecules was screened in the duplexed format. Small molecule modulators identified in the screen were confirmed in a traditional fluorescence-based polymerase strand-displacement assay and an orthogonal label-free binding assay using SAMDI affinity selection mass spectrometry (ASMS). This work demonstrates the flexibility of high-throughput mass spectrometry approaches in drug discovery and highlights a novel application of SAMDI technology that opens new avenues for multiplexed high-throughput screening.
聚合酶 β(POLB)具有连接酶和聚合酶的双重功能,在碱基切除修复(BER)途径中发挥关键作用,以维持基因组稳定性。在 BRCA1/2 突变型癌细胞系中进行的 POLB 敲除和挽救研究表明,抑制连接酶和聚合酶活性对于观察到的与 PARP 抑制剂的合成致死相互作用是必需的,这突显了 POLB 作为有价值的治疗靶点。传统的生化筛选酶抑制剂的方法侧重于单个底物到产物关系,限制了对 POLB 等利用多种底物或催化多步反应的酶的全面分析。本报告描述了第一个基于高通量质谱的筛选方法,该方法使用双串联自组装单层解吸电离(SAMDI)质谱方法,在单个测定中测量 POLB 的两种不同生化活性。优化了动力学平衡条件,开发了用于 POLB 双酶活性的多重测定法,并在双串联格式下筛选了 20 万个不同的小分子。在筛选中鉴定的小分子调节剂在传统的基于荧光的聚合酶链置换测定法和使用 SAMDI 亲和选择质谱(ASMS)的正交无标记结合测定法中得到了证实。这项工作证明了高通量质谱方法在药物发现中的灵活性,并突出了 SAMDI 技术的新应用,为多重高通量筛选开辟了新途径。